Smart-Money SignalNeutral · 48/100— Insiders are net sellers over 90 days (-$6.3M, 10 sales vs 1 buy)
Net Income-$69.7M
EPS$-0.98
Market Cap$1.5B
Price Performance
Historical data including institutional events
Company Profile
J
Jorge da Silva
CEO & Executive Director
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
The company was founded in 2021 and is headquartered in Zug, Switzerland.
